Donor-Derived T-Cell Redirection With Epcoritamab Achieving Complete Response After Early Post-Allo-HSCT Relapse of
Yoshikazu Ikoma1,2, Yuto Kaneda1, Ryoma Shimazu1,3
1Department of Hematology and Infectious Disease Gifu University Hospital Gifu Japan.
Background:
Epcoritamab, a bispecific CD3×CD20 antibody, offers a promising treatment for relapsed diffuse large B-cell lymphoma (DLBCL). Its efficacy and safety after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain unclear.
Case Report:
In a 64-year-old man with relapsed DLBCL, epcoritamab showed limited efficacy, achieving stable disease prior to allo-HSCT; nevertheless, re-administration after donor T-cell engraftment resulted in a complete response without severe graft-versus-host disease or cytokine release syndrome.
Conclusions:
This observation suggests that donor-derived T-cell redirection with epcoritamab may enhance antitumor efficacy while maintaining safety in the post-transplant setting, supporting its potential as a salvage therapy for relapsed DLBCL post-allo-HSCT.
More Related Videos
11:59Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
Published on: September 6, 2017
09:29Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
Published on: February 1, 2013